Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected a poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, over 32%, from $109.11 to $73.89 [6]. Legal Proceedings - Investors have until February 9, 2026, to request to lead the case in the U.S. District Court for the Southern District of New York, under the case caption West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al. [3]. Legal Representation - Bleichmar Fonti & Auld LLP, a leading law firm in securities class actions, is representing the plaintiffs in this case, emphasizing that there are no costs to shareholders for litigation [7][8].

Core Insights - A class action has been filed against Integer Holdings Corporation (NYSE: ITGR) on behalf of investors who acquired its securities between July 25, 2024, and October 22, 2025, alleging misleading statements regarding the demand for its products [1][2] Allegations - The complaint claims that Integer Holdings misled investors about its market position in the electrophysiology (EP) market and overstated the demand for its EP devices, which had actually seen a significant decline [2] - Revenue growth from Integer's EP devices was reported to be decelerating, contrary to the company's claims of outpacing market growth [2] Financial Performance - On October 23, 2025, Integer revised its full-year 2025 guidance, projecting net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026 [3] - The company acknowledged that two of its PE devices had slower-than-expected market adoption, with this trend anticipated to continue into 2026 [3] - Following this announcement, Integer's stock price dropped by $35.22, or over 32%, closing at $73.89 per share [3] Legal Proceedings - Shareholders interested in participating in the class action must submit their papers by February 9, 2026, to serve as lead plaintiff [4] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Integer Holdings Corporation regarding a class action lawsuit alleging that the company made materially false and misleading statements about its competitive position and sales performance in the electrophysiology manufacturing market [1][2]. Group 1: Allegations - The complaint alleges that Integer Holdings Corporation overstated its competitive position within the electrophysiology manufacturing market [1]. - It is claimed that despite the company's assertions of strong visibility into customer demand, there was a sustained deterioration in sales for two of its electrophysiology devices [1]. - The company mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment, leading to misleading positive statements about its business and operations [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as July 25, 2024, to October 22, 2025 [1]. - Shareholders are encouraged to register for the class action by February 9, 2026, to potentially be appointed as lead plaintiffs [2]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer announced a reduction in its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6] - The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, alongside slower adoption rates for two of its EP devices [6] - Following this announcement, Integer's stock price plummeted by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6]. Legal Proceedings - Investors have until February 9, 2026, to request to lead the case in the U.S. District Court for the Southern District of New York, under the case caption West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al. [3]. Legal Representation - Bleichmar Fonti & Auld LLP, a leading law firm in securities class actions, is representing the plaintiffs in this case, with a history of recovering significant amounts for investors in previous cases [8].

Core Points - The article highlights the upcoming deadline of February 9, 2026, for investors to file a lead plaintiff motion in a case concerning Integer Holdings Corporation (NYSE: ITGR) [1] - The case is specifically for investors who purchased common stock of Integer Holdings between July 25, 2024, and October 22, 2025, which is referred to as the "Class Period" [1] Company Information - Integer Holdings Corporation is the subject of a legal case that may impact its investors [1] - The law offices of Howard G. Smith are reminding affected investors to take action regarding their potential losses [1]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - A class action securities lawsuit has been filed against Integer Holdings Corporation, alleging securities fraud that adversely affected investors between July 25, 2024, and October 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Integer Holdings materially overstated its competitive position in the electrophysiology manufacturing market [2]. - It is alleged that despite claims of strong visibility into customer demand, the company was experiencing a sustained decline in sales related to two of its electrophysiology devices [2]. - The complaint further asserts that Integer mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment [2]. - As a result of these issues, the positive statements made by the defendants regarding the company's business and prospects were deemed materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until February 9, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its EP devices while public assurances contradicted the actual decline in demand and revenue [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' estimates [6]. Group 3: Stock Impact - Following the announcement of lowered sales guidance, Integer's stock price dropped by $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Integer Holdings Corporation on behalf of investors who purchased its common stock during the specified class period from July 25, 2024, to October 22, 2025 [1] Group 1 - The lawsuit is initiated by Glancy Prongay & Murray LLP, a prominent national shareholder rights law firm [1] - Investors have until February 9, 2026, to file a lead plaintiff motion [1]